BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma
BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma
Recruiting · NCT06745687 · Registry updated 2026-07-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma | High Risk Smoldering Multiple Myeloma | Recruiting | Not applicable | 2026-07-23 | NCT06745687 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | 285 |
| Keymed Biosciences Co.Ltd | 28 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences | Tianjin | China | 10 |